# Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

> **NCT05493566** · EARLY_PHASE1 · RECRUITING · sponsor: **Emory University** · enrollment: 15 (estimated)

## Conditions studied

- Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05493566
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2027-01-07
- **Final completion:** 2028-01-07
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05493566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05493566, "Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05493566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*